share_log

Sanofi | 6-K: New Phase 2b Results for Amlitelimab Support Potential for Best-in-Class Maintenance of Response in Atopic Dermatitis

Sanofi | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

賽諾菲安萬特 | 6-K:外國發行人報告
美股SEC公告 ·  03/21 02:13
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息